CN104837844B - 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 - Google Patents

作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 Download PDF

Info

Publication number
CN104837844B
CN104837844B CN201380066075.3A CN201380066075A CN104837844B CN 104837844 B CN104837844 B CN 104837844B CN 201380066075 A CN201380066075 A CN 201380066075A CN 104837844 B CN104837844 B CN 104837844B
Authority
CN
China
Prior art keywords
compound
substituted
mmol
fluorophenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380066075.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104837844A (zh
Inventor
U.维拉帕蒂
C.P.达恩
D.S.多德
刘培英
C.P.穆萨里
M.D.维特曼
S.库马拉维尔
D.马利克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN104837844A publication Critical patent/CN104837844A/zh
Application granted granted Critical
Publication of CN104837844B publication Critical patent/CN104837844B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380066075.3A 2012-12-21 2013-12-20 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 Expired - Fee Related CN104837844B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740552P 2012-12-21 2012-12-21
US61/740552 2012-12-21
PCT/US2013/076806 WO2014100540A1 (en) 2012-12-21 2013-12-20 Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors

Publications (2)

Publication Number Publication Date
CN104837844A CN104837844A (zh) 2015-08-12
CN104837844B true CN104837844B (zh) 2017-08-29

Family

ID=49943574

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380066075.3A Expired - Fee Related CN104837844B (zh) 2012-12-21 2013-12-20 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪

Country Status (5)

Country Link
US (1) US9475817B2 (enExample)
EP (1) EP2935272B1 (enExample)
JP (1) JP6283688B2 (enExample)
CN (1) CN104837844B (enExample)
WO (1) WO2014100540A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2935271B1 (en) 2012-12-21 2017-10-25 Bristol-Myers Squibb Company Novel substituted imidazoles as casein kinase 1 / inhibitors
EP3157925B1 (en) 2014-06-19 2019-12-18 Bristol-Myers Squibb Company Imidazo-pyridazine derivatives as casein kinase 1 delta/epsilon inhibitors
EP4591936A3 (en) 2015-03-23 2025-10-15 Tianli Biotech Pty Ltd Treatment of respiratory diseases
CN105418615B (zh) * 2015-12-09 2018-02-02 北京工业大学 苯甲酰胺衍生物及制备和应用
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
WO2020093098A1 (en) 2018-11-07 2020-05-14 The University Of Melbourne Novel compounds for the treatment of respiratory diseases
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3139285A1 (en) * 2019-06-27 2020-12-30 Hangzhou Healzen Therapeutics Co., Ltd. Casein kinase 1e inhibitor, pharmaceutical composition and application thereof
CN112451529A (zh) * 2020-12-18 2021-03-09 忻佑康医药科技(南京)有限公司 Kb-NB 142-70的药物新用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009037394A2 (fr) * 2007-07-19 2009-03-26 Sanofi-Aventis DERIVES DE 6-CYCLOAMINO-S-(PYRIDAZIN-YL)IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.
EP2058309A1 (en) * 2006-08-04 2009-05-13 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN101981033A (zh) * 2008-02-06 2011-02-23 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
CN102256979A (zh) * 2008-12-19 2011-11-23 赛诺菲 6-环氨基-2-噻吩基-3-(吡啶-4-基)咪唑并[1，2-b]哒嗪和6-环氨基-2-呋喃基-3-(吡啶-4-基)咪唑并[1，2-b]哒嗪的衍生物，其制备和治疗用途
CN102325773A (zh) * 2008-12-19 2012-01-18 赛诺菲 6-环氨基-2,3-二吡啶基咪唑并[1,2-b]-哒嗪衍生物及其制备和治疗应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
PL3181133T3 (pl) * 2010-12-20 2019-12-31 Pfizer Inc. Nowe skondensowane związki pirydyny jako inhibitory kinazy kazeiny
EP2935271B1 (en) 2012-12-21 2017-10-25 Bristol-Myers Squibb Company Novel substituted imidazoles as casein kinase 1 / inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058309A1 (en) * 2006-08-04 2009-05-13 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2009037394A2 (fr) * 2007-07-19 2009-03-26 Sanofi-Aventis DERIVES DE 6-CYCLOAMINO-S-(PYRIDAZIN-YL)IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.
CN101981033A (zh) * 2008-02-06 2011-02-23 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
CN102256979A (zh) * 2008-12-19 2011-11-23 赛诺菲 6-环氨基-2-噻吩基-3-(吡啶-4-基)咪唑并[1，2-b]哒嗪和6-环氨基-2-呋喃基-3-(吡啶-4-基)咪唑并[1，2-b]哒嗪的衍生物，其制备和治疗用途
CN102325773A (zh) * 2008-12-19 2012-01-18 赛诺菲 6-环氨基-2,3-二吡啶基咪唑并[1,2-b]-哒嗪衍生物及其制备和治疗应用

Also Published As

Publication number Publication date
CN104837844A (zh) 2015-08-12
EP2935272A1 (en) 2015-10-28
JP6283688B2 (ja) 2018-02-21
US20150344480A1 (en) 2015-12-03
WO2014100540A1 (en) 2014-06-26
US9475817B2 (en) 2016-10-25
EP2935272B1 (en) 2017-02-22
JP2016508135A (ja) 2016-03-17

Similar Documents

Publication Publication Date Title
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
US9956220B2 (en) Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
US8445676B2 (en) Pyrrolotriazine kinase inhibitors
JP5225288B2 (ja) キナーゼ阻害剤として有用なチアゾリル化合物
WO2011123493A1 (en) Substituted pyrrolotriazines as protein kinase inhibitors
KR102039764B1 (ko) 신규 티에노피리미딘 유도체, 그의 제조 방법 및 그의 치료 용도
CN102740698A (zh) 用于激酶调节的化合物和方法及其适应症
EA029312B1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
US9550796B2 (en) Pyrrolopyrrolone derivatives and their use as BET inhibitors
CN101679406A (zh) 用作激酶抑制剂的噻唑基化合物
CN114401955A (zh) 细胞周期蛋白依赖性激酶的抑制剂
KR20160079092A (ko) Gsk-3 억제제로서 유용한 치환된 피리딘 유도체
WO2020010003A1 (en) AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
ES2942442T3 (es) Derivados de [1,2,4]triazolo[4,3-a]pirazin-8-ona

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170829

Termination date: 20211220